Loading
Georgiamune
Georgiamune is a United States-based biotechnology company running 2 late-stage cancer trials of GIM122 and GIM-531 in melanoma.
Also called: Georgiamune Inc
Overview
Georgiamune, based in Gaithersburg, the United States, is a biotechnology company. Georgiamune develops immunotherapies that reprogram immune signalling pathways to rebalance immune system components, for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GIM122 and GIM-531 in melanoma. The largest, NCT06425926 (Safety and Tolerability Study of GIM-531 in Advanced Solid Tumours), plans to enrol 117 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Connected
5Similar pages
- CompanyHiberCell
Shares Pivotal (registrational) trial, Clinical trial, Melanoma.
- CompanyPregLem
- CompanyIdera Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Melanoma.
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
georgiamune.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/